Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Key Stats

• Today's Range: $1.84 to $1.89
• 50-Day Range: $1.62 to $2.03
• 52-Week Range: $1.60 to $3.14
• Volume: 1.46 million shs
• Average Volume: 1.34 million shs
• Market Capitalization: $713.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: N/A

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 28% of companies evaluated by MarketBeat, and ranked 722nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: N/A

Amount of Analyst Coverage

Cronos Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cronos Group are expected to grow in the coming year, from ($0.03) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Cronos Group has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.04% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently decreased by 4.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.04% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently decreased by 4.27%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Cronos Group has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cronos Group this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Cronos Group is held by insiders.

Percentage Held by Institutions

Only 8.71% of the stock of Cronos Group is held by institutions.

CRON Stock Analysis - Frequently Asked Questions

How have CRON shares performed this year?

Cronos Group's stock was trading at $2.02 at the start of the year. Since then, CRON stock has decreased by 8.4% and is now trading at $1.85.
View the best growth stocks for 2025 here.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) announced its earnings results on Thursday, August, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter. The company earned $27.76 million during the quarter, compared to the consensus estimate of $25.85 million. Cronos Group had a negative net margin of 42.65% and a negative trailing twelve-month return on equity of 2.56%.
Read the conference call transcript.

Who are Cronos Group's major shareholders?

Cronos Group's top institutional shareholders include SeaCrest Wealth Management LLC (0.08%), Formidable Asset Management LLC (0.07%) and IMC Chicago LLC.
View institutional ownership trends.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 5/07/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRON
• CIK: 1656472
• Web: www.thecronosgroup.com
• Phone: (416) 504-0004
• Fax: N/A
• Employees: 450
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $3.50
• Low Stock Price Target: $3.50
• Potential Upside/Downside: +89.7%
• Consensus Rating: N/A
• Rating Score (0-4): 0.00
• Research Coverage: 0 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.10
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 1.74
• Net Income: $-73,960,000.00
• Net Margins: -42.65%
• Pretax Margin: -49.33%
• Return on Equity: -2.56%
• Return on Assets: -2.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.24
• Quick Ratio: 23.05

Sales & Book Value

• Annual Sales: $117.62 million
• Price / Sales: 6.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 385,407,000
• Free Float: 356,136,000
• Market Cap: $711.08 million
• Optionable: Optionable
• Beta: 1.06